# Carnosine Sleep Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/carnosine-sleep-meta-analysis-evidence-review
Category: evidence-review
Summary: Carnosine Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomize
Last reviewed: 2026-07-28
Reviewed by: Migaku Evidence Review
# Carnosine Sleep Meta-analysis: What the Evidence Says

## Quick Answer

Carnosine Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Effect of Carnosine Supplementation on Depressive Symptoms and Health‐Related Quality of Life in Individuals With Prediabetes and Well‐Controlled Type 2 Diabetes: A Randomized Controlled Trial | randomized trial | 2 | 2026-02-25 | 10.1002/fsn3.71514 |
| Essential amino acid supplementation for pressure ulcers: pathophysiological rationale and results from a pilot study | preclinical study | 4 | 2025-11-14 | 10.1007/s00726-025-03489-8 |

## What The Sources Report

- Individuals with T2DM have a higher risk of mental health disorders (Arias et al. ; Deshpande et al. ; Ducat et al. ), with the prevalence of depression reported to be two-fold higher in those with T2DM compared with the general population (Roy and Lloyd ). [Kabthymer Robel Hussen (2026); evidence level 2]
- Similarly, the prevalence of depression is moderately increased in individuals with prediabetes compared with their normo-glycaemic counterparts (Chen et al. ). [Kabthymer Robel Hussen (2026); evidence level 2]
- The other recent systematic review and meta-analysis (Song et al.) showed that older patients living with PU experience two times higher risk of mortality than those who do not have such wounds. [Świątkiewicz Maciej (2025); evidence level 4]
- The first such systems were designed in the 1950 s and later several others were proposed, but according to some authors, there is no evidence that anyone is superior (Kottner et al.). [Świątkiewicz Maciej (2025); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For carnosine sleep meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Kabthymer Robel Hussen (2026). The Effect of Carnosine Supplementation on Depressive Symptoms and Health‐Related Quality of Life in Individuals With Prediabetes and Well‐Controlled Type 2 Diabetes: A Randomized Controlled Trial. DOI: 10.1002/fsn3.71514. PMCID: PMC12935567. PMID: 41767833. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12935567/
- Świątkiewicz Maciej (2025). Essential amino acid supplementation for pressure ulcers: pathophysiological rationale and results from a pilot study. DOI: 10.1007/s00726-025-03489-8. PMCID: PMC12618284. PMID: 41236568. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12618284/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.